Article

Study targets intravitreal injections for AMD, PCR risks

Author(s):

Marta Belmonte-Grau, MD discusses the potential risk for posterior capsular rupture during cataract surgery.


Posterior capsular rupture (PCR) is the most frequent complication during cataract surgery in patients treated previously with intravitreal anti-vascular endothelial growth factor (VEGF) injections for age-related macular degeneration (AMD), according to Marta Belmonte-Grau, MD.

During a presentation at the EURETINA 2021 Virtual Congress, Belmonte-Grau reported that this was especially true for patients with a posterior subcapsular cataract and likely the result of needle-induced trauma to the posterior capsule during injection. Belmonte-Grau is from the Hospital Universitario de la Princesa, Madrid.

Belmonte-Grau and her colleagues retrospectively reviewed the charts of patients undergoing phacoemulsification at their institution.

They evaluated patient age, gender, operated eye, presence of risk factors for surgical complications, duration of intravitreal treatment (≤6 or >6 months), number of preoperative intravitreal injections (≤10 or >10), surgeon experience (≤5 or >5 years), and initial/final visual acuity (VA). All patients had received previous anti-VEGF injections for AMD. The primary outcome measure was the occurrence of intraoperative PCR.

A total of 550 cataract surgeries were reviewed, with 83 eyes (15.09%; 57 women, 26 men; mean age, 84.52 years) having received previous intravitreal injections.

The investigators identified 20 eyes with a posterior subcapsular cataract (24.10%), 3 eyes (3.60%) with poor dilation, 2 eyes (2.40%) with mature cataract, and 1 eye (1.20%) with pseudoexfoliation syndrome.

“Patients with posterior subcapsular cataract had an odds ratio of 5.67 (95% confidence interval [CI], 5.67-5.67; p<0.05) for occurrence of an intraoperative complication,” investigators reported. “Regarding the complication rate, complications developed in 10 eyes (12.05%) during cataract surgery. The most frequent cause was dislocation of the nucleus into the vitreous (n=5, 6%) followed by PCR (n=3, 3.60%) and zonular disinsertion (n=2, 2.40%).”

Univariate analysis showed increased VA 6 months postoperatively (mean gain, 0.43 line). Surgeon experience and number of previous intravitreal injections were not significant risk factors for PCR.

With cataract surgery the most frequently performed surgery and the aging of the population, elderly women are the typical patients treated with intravitreal injections for AMD, Belmonte-Grau explained.

“PCR occurs more frequently during cataract surgery in patients who were treated previously with intravitreal injections and especially those with a posterior subcapsular cataract, probably caused by needle-induced trauma to the posterior capsule during injection,” she concluded. “We emphasize thorough evaluation of the cataract preoperatively in these patients. A large majority of the complications had to be treated with vitrectomy, so this eventuality must be included in the informed consent and the information provided to patients.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.